Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, tirzepatide, liraglutide, dulaglutide ...

Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Other GLP-1 agonists, including Zepbound ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type ... of patients discontinue GLP-1 RA therapy within the ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...